A detailed history of High Vista Strategies LLC transactions in Merus N.V. stock. As of the latest transaction made, High Vista Strategies LLC holds 73,980 shares of MRUS stock, worth $3.32 Million. This represents 1.45% of its overall portfolio holdings.

Number of Shares
73,980
Previous 116,718 36.62%
Holding current value
$3.32 Million
Previous $6.91 Million 46.48%
% of portfolio
1.45%
Previous 2.77%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$47.19 - $58.84 $2.02 Million - $2.51 Million
-42,738 Reduced 36.62%
73,980 $3.7 Million
Q2 2024

Aug 14, 2024

SELL
$39.81 - $60.2 $197,537 - $298,712
-4,962 Reduced 4.08%
116,718 $6.91 Million
Q1 2024

May 15, 2024

SELL
$28.03 - $51.82 $333,332 - $616,243
-11,892 Reduced 8.9%
121,680 $5.48 Million
Q4 2023

Feb 14, 2024

BUY
$20.06 - $28.66 $219,476 - $313,569
10,941 Added 8.92%
133,572 $3.67 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $1.78 Million - $2.42 Million
88,604 Added 260.39%
122,631 $2.89 Million
Q2 2023

Aug 14, 2023

SELL
$18.33 - $27.18 $218,676 - $324,257
-11,930 Reduced 25.96%
34,027 $895,000
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $654,887 - $942,118
45,957 New
45,957 $845,000
Q3 2022

Nov 14, 2022

SELL
$18.64 - $28.93 $64,997 - $100,878
-3,487 Reduced 8.61%
36,994 $741,000
Q2 2022

Aug 15, 2022

BUY
$13.98 - $29.25 $141,100 - $295,220
10,093 Added 33.21%
40,481 $916,000
Q1 2022

May 16, 2022

SELL
$23.58 - $30.91 $552,998 - $724,901
-23,452 Reduced 43.56%
30,388 $803,000
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $1.08 Million - $1.74 Million
53,840 New
53,840 $1.71 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.06B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track High Vista Strategies LLC Portfolio

Follow High Vista Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Vista Strategies LLC with notifications on news.